Roche’s Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line treatment of people with previously untreated locally advanced or metastatic urothelial carcinoma eligible and ineligible for cisplatin chemotherapy, has been very positive, and indeed is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer. The Tecentriq combination reduced the risk of disease deterioration or death compared with chemotherapy alone at 8.2 months versus 6.3 months. Overall survival results were encouraging in the intention-to-treat population at 16 months vs 13.4 months, albeit statistical significance was not reached at this point. Safety in the combination was consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.
“Phase III IMvigor130 study yields positive results“
Sandra Horning, Chief Medical Officer and Head of Global Product Development at Roche, said: “We are pleased with these positive results from the IMvigor130 study, which show Tecentriq plus chemotherapy may provide a meaningful benefit for people newly diagnosed with advanced bladder cancer. There remains a high unmet need for people with advanced bladder cancer, where chemotherapy alone is the current standard of care. These results reinforce the role of immunotherapy in treating this aggressive disease.”